Cochlear Ltd.

Sanofi’s investment marks the entry of a strategic shareholder Support from existing investors Redmile Group, Artal, which is advised by Invus, and Sofinnova Partners Participation from leading U.S. Healthcare Specialists funds including Cormorant Asset Management, Coastlands Capital and Sphera Healthcare Cash runway extended until H1 2027, supporting key catalysts including SENS-601 (GJB2-GT) CTA/IND approval and first cohort enrollment, as well as the continued clinical advancement of SENS-501 MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced a €60 million offering reserved to specific categories of investors (the “ Reserved Offering ”) through the issuance of 214,285,714 new ordinary shares of the Company (the “ New Shares ”) at a price per New Share of €0.28 (the “ Subscription Price ”) to the benefit of Sanofi for €20 million, and Redmile Group, Artal, which is advised by Invus, and Sofinnova Partners, existing shareholders, and other investors including Cormorant Asset Management, Coastlands Capital and Sphera Healthcare, for €40 million. The settlement-delivery of the Reserved Offering is expected to take place around January 30 th , 2026, subject to customary conditions. Sanofi’s investment and participating investors will drive the progression of the genetic medicine pipeline, notably SENS-601 (GJB2-GT). This funding supports key catalysts for the program which targets hearing loss associated with GJB2 mutations, including CTA/IND approval and the enrollment of the first clinical cohort. SENS-601 (GJB2-GT) will be the Company’s second gene therapy program to enter the clinic, following SENS-501, which entered clinical development in 2024. The program targets GJB2 mutations, which are responsible for a significantly larger patient population, accounting for approximately 50% of autosomal recessive non-syndromic congenital hearing loss and implicated in early-onset forms of severe presbycusis in adults. Nawal Ouzren, Chief Executive Officer of Sensorion , said: “ We welcome Sanofi’s new strategic investment in Sensorion to advance our pipeline of innovative therapies intended to improve the quality of life of patients suffering from hearing disorders. We are very thankful to the top-tier new investors who joined us and express our gratitude to our existing shareholders who have reaffirmed their support in this transaction. With the additional capital, the Company plans to intensify the ongoing efforts to progress the research and development of SENS-601, including the advancement of the program into its clinical development, and to continue the clinical development of SENS-501 program. This marks an important milestone for the Company’s corporate growth trajectory and for patients suffering from a variety of hearing loss disorders .” Expected next clinical milestones Q1 2026 – SENS-501: Cohort two 6-months follow-up data of Phase 1/2 Audiogene trial Q1 2026 – SENS-401 in Cisplatin-induced Ototoxicity: Notoxis Phase 2a data readout Q1 2026 – SENS-601 (GJB2-GT): Clinical Trial Application Submission Impact on cash flow and use of proceeds The Company intends to use the net proceeds from the Reserved Offering, which amount to circa €56 million, to fund principally the company’s R&D activities related to its Gene Therapy programs, SENS-501 and SENS-601 (GJB2-GT), evenly, as well as for other R&D and corporate overhead expenses. Together with cash & cash equivalent and short-term deposits considered by the Company as liquid and easily available, amounting to c. €47.3 million (unaudited) as of December 31st, 2025, the Company believes that it will have sufficient cash & cash equivalent to fund its operations until the end of H1 2027 (based on its projected expenditures, the Company estimated that its cash and cash equivalents, prior to the Reserved Offering, would enable it to finance its activities into Q3 2026). The Company continues to pursue non-dilutive financing for the other assets. Main terms of the Reserved Offering Sensorion’s Board of Directors and, by sub-delegation of the Board of Directors, the Chief Executive Officer, using the delegation of powers granted by the 15 th resolution of the ordinary and extraordinary shareholders’ general meeting held on May 12 th , 2025 (capital increase with cancellation of preferential subscription rights in favor of categories of persons with specific characteristics) and in accordance with Article L. 225-138 et seq . of the French Commercial Code ( Code de commerce ), have decided respectively on January 27 th , 2026 and January 28 th , 2026, to complete the issuance of the 214,285,714 New Shares. The New Shares were issued at a price of €0.28, which represents a 0.4% discount to the last closing price and a discount of 2.0% to the weighted average share price on the day preceding the date on which the issuance price is set (i.e. January 27 th 2026), in accordance with the 15 th resolution of the ordinary and extraordinary shareholders’ meeting of the Company held on May 12 th , 2025. The issuance of the 214,285,714 New Shares will result in an immediate capital increase of €59,999,999.92 (i.e., a nominal amount of €21,428,571.40 and a total issuance premium of €38,571,428.52 and corresponding to a nominal value of 10 cents (€0.10) plus an issuance premium of €0.18 per New Share), representing approximately 71% of the Company’s share capital and voting rights outstanding before the Reserved Offering. Redmile Group, Artal, which is advised by Invus, and Sofinnova Partners who are existing shareholders and are also represented on the Board of Directors of the Company, will participate in the Reserved Offering for subscription amounts of €5.3 million, €6.5 million and €3.0 million, respectively, representing 9%, 11% and 5% of the aggregate gross amount of the Reserved Offering, respectively. It is specified that Redmile Group, Artal, which is advised by Invus, and Sofinnova Partners, who are also members of Sensorion’s Board of Directors, did not take part in the vote of the Reserved Offering at the Board of Directors’ meeting held on January 27 th , 2026. Following the settlement-delivery expected to occur on January 30 th , 2026, the Company's total share capital will be €51,494,694.00 divided into 514,946,940 ordinary shares, each with a par value of €0.10. The New Shares will be fungible with the existing ordinary shares of the Company and will be admitted to trading on Euronext Growth in Paris under the ISIN FR0012596468. Leerink Partners LLC (“ Leerink Partners ”) and Stifel Europe Limited (“ Stifel ”) are acting as lead placement agents in connection with the Reserved Offering. Robert W. Baird & Co. Incorporated (“ Baird ”) is acting as placement agent in connection with the Reserved Offering (Leerink Partners together with Stifel and Baird, the “ Placing Agents ”). Stifel is acting as Centralizing Agent. Namsen Capital is acting as equity capital markets advisor. Shareholding Structure after the Reserved Offering On an illustrative basis, a shareholder holding 1% of the Company's share capital before the Reserved Offering and who did not participate in the Reserved Offering will hold 0.58% of the Company's share capital after the issuance of the New Shares. To the Company's knowledge, the shareholding structure, on a non-diluted basis, before and after the Reserved Offering, breaks down as follows. Based on the information available to the Company, the share capital of the Company before the Offering is as follows: Shareholding Structure as of December 31st, 2025 (non-diluted) Shareholding Structure as of December 31st, 2025 (fully diluted) Number of shares Number of shares (%) Number of Voting Rights Number of Voting Rights (%) Number of shares that might be issued or vested Number of shares and diluted shares % of diluted share capital % of diluted voting rights Redmile Group LLC 66,052,590 22.0% 66,052,590 22.0% 17,857,143 83,909,733 24.9% 24.9% Fynveur (Artal) 80,980,547 26.9% 80,980,547 27.0% - 80,980,547 24.0% 24.1% Sofinnova Partners 54,337,460 18.1% 54,337,460 18.1% - 54,337,460 16.1% 16.1% Sonova AG 2,941,176 1.0% 2,941,176 1.0% - 2,941,176 0.9% 0.9% Cochlear 533,755 0.2% 533,755 0.2% - 533,755 0.2% 0.2% Subtotal 204,845,528 68.1% 204,845,528 68.2% 17,857,143 222,702,671 66.1% 66.2% Officers 160,000 0.1% 160,000 0.1% 10,057,801 10,217,801 3.0% 3.0% Directors - 0.0% - 0.0% 1,525,202 1,525,202 0.5% 0.5% Other Employees - 0.0% - 0.0% 5,342,034 5,342,034 1.6% 1.6% Treasury shares 314,000 0.1% - 0.0% - 314,000 0.1% - Other Institutional Shareholder and Free Float 95,341,698 31.7% 95,341,698 31.7% 1,499,858 96,841,556 28.7% 28.8% TOTAL 300,661,226 100.0% 300,347,226 100.0% 36,282,038 336,943,264 100.0% 100.0% The share capital of the Company following the issuance of the ordinary shares in the Offering is as follows: Shareholding structure (non-diluted) Shareholding structure (fully diluted) Number of shares Number of shares (%) Number of Voting Rights Number of Voting Rights (%) Number of shares that might be issued or vested Number of shares and diluted shares % of diluted share capital % of diluted voting rights Redmile Group LLC 84,981,161 16.5% 84,981,161 16.5% 17,857,143 102,838,304 18.7% 18.7% Fynveur (Artal) 104,194,832 20.2% 104,194,832 20.2% - 104,194,832 18.9% 18.9% Sofinnova Partners 65,051,745 12.6% 65,051,745 12.6% - 65,051,745 11.8% 11.8% Sanofi 71,428,571 13.9% 71,428,571 13.9% - 71,428,571 13.0% 13.0% Other existing and new investors 90,000,002 17.5% 90,000,002 17.5% - 90,000,002 16.3% 16.3% Sonova AG 2,941,176 0.6% 2,941,176 0.6% - 2,941,176 0.5% 0.5% Cochlear 533,755 0.1% 533,755 0.1% - 533,755 0.1% 0.1% Subtotal 419,131,242 81.4% 419,131,242 81.4% 17,857,143 436,988,385 79.3% 79.3% Officers 160,000 0.0% 160,000 0.0% 10,057,801 10,217,801 1.9% 1.9% Directors - 0.0% - 0.0% 1,525,202 1,525,202 0.3% 0.3% Other Employees - 0.0% - 0.0% 5,342,034 5,342,034 1.0% 1.0% Treasury shares 314,000 0.1% - 0.0% - 314,000 0.1% - Other Institutional Shareholder and Free Float 95,341,698 18.5% 95,341,698 18.5% 1,499,858 96,841,556 17.6% 17.6% TOTAL 514,946,940 100.0% 514,632,940 100.0% 36,282,038 551,228,978 100.0% 100.0% Lock-up agreements In connection with the Reserved Offering, the Company has entered into a lock-up agreement restricting the issuance of additional ordinary shares for a period ending 90 days following the execution of the subscription agreement entered into with the investors, subject to customary exceptions. The Company’s management, Board members and shareholders represented at the Board of Directors who hold ordinary shares of the Company are also subject to a lock-up for a period of 90 days following the execution of the subscription agreement entered into with the investors, subject to customary exceptions. Settlement-delivery of the Reserved Offering The admission of the New Shares to trading on the Euronext Growth market in Paris is scheduled for the time of settlement and delivery, which is expected to take place on January 30 th , 2026. The New Shares will be immediately assimilated to the Company's existing shares already traded on Euronext Growth in Paris, and will be able to be traded, from their issuance, on the same listing line (ISIN code: FR0012596468). The Reserved Offering has not given rise to a prospectus submitted for approval by the AMF. Risk Factors The Company draws the public’s attention to the risk factors related to the Company and its activities presented in section 2.5 of the “ Rapport Semestriel ” for the half-year ended June 30 th , 2025, which is available free of charge on the website of the Company ( ). In addition, investors are invited to consider the following risks: (i) shareholders stake in the Company will be diluted further to the issuance of the New Shares, for the shareholders who did not participate to the Reserved Offering (ii) the market price for the Company's shares may fluctuate and fall below the subscription price of the shares issued pursuant to the Reserved Offering, (iii) the volatility and liquidity of the Company's shares may fluctuate significantly, (iv) sales of the Company’s shares may occur on the market and have a negative impact on the market price of the shares, and (v) the Company’s shareholders could undergo a potentially material dilution resulting from any future capital increases that are needed to finance the Company. About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve the diagnosis of these underserved illnesses. Sensorion’s portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion’s small molecule progressed in three Phase 2 proof of concept clinical study: firstly, in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing, for which the recruitment is completed, and the follow-up is ongoing. Secondly, with partner Cochlear Limited, a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation, completed in 2024. Thirdly, a Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in 2022. Label: SENSORION ISIN: FR0012596468 Mnemonic: ALSEN Forward-looking statements This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith. Disclaimer This press release does not constitute an offer to sell or the solicitation of an offer to buy ordinary shares of the Company, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. This announcement is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the “Prospectus Regulation”). In France, the Reserved Offering described above is exclusively carried out in the form of a placement to qualified investors as defined by Article 2(e) of the Prospectus Regulation and to specific category of investors, in accordance with Article L. 225-138 of the French Commercial Code ( Code de commerce ) and applicable regulations. With respect to Member States of the European Economic Area (including France), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release which would require the publication of a prospectus (pursuant to Article 3 of the Prospectus Regulation) in any Member State. This press release and the information it contains is not an offer to sell, nor the solicitation of an offer to subscribe for or buy the New Shares in the United States or any other jurisdiction where restrictions may apply including notably Canada, Australia or Japan. Securities may not be offered or sold in the United States absent registration under the Securities Act or an exemption from registration thereunder. Sensorion does not intend to register the New Shares under the Securities Act or conduct a public offering of the New Shares in France, the United States, or in any other jurisdiction. This communication is being distributed only to, and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents. This distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restriction. Contacts Investor Relations Sensorion Nicolas Bogler, Investor Relations and Communication ir.contact@sensorion-pharma.com Press Relations Maarc Communication Bruno Arabian / 00 33(0)6 87 88 47 26 bruno.arabian@maarc.fr Nicolas Entz / 00 33 (0)6 33 67 31 54 nicolas.entz@maarc.fr

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Data Monitoring Committee (DMC) supports the continuation of the Audiogene Phase 1/2 clinical trial of SENS-501, the Company’s gene therapy program being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. Based on the DMC’s safety observations to date which include good procedural tolerance, the Committee has raised no safety concerns. The Audiogene trial is designed to evaluate the safety, tolerability and efficacy of intra-cochlear administration of SENS-501 for the treatment of OTOF gene-mediated hearing loss in paediatric patients aged 6 to 31 months at the time of treatment. By intervening during the critical early window of brain plasticity and enrolling infants who have not yet received a cochlear implant, the study aims to isolate the therapeutic effect of SENS-501 as monotherapy. The trial consists of two sequential dose-escalation cohorts, each involving unilateral injection to allow a clear assessment of the kinetics of hearing restoration. Moreover, Audiogene aims to evaluate the usability, the clinical and the technical performances of the injection system in development. On December 4th, the DMC reviewed the first part of the SENS-501 Audiogene Phase 1/2 clinical trial including cohort 2 which completed enrolment in July 2025. This cohort includes three patients aged between 6 and 31 months who received the dose 2 of SENS-501 (4.5E11 vg/vector/ear). Across both the first and second cohorts, the surgical procedure was well tolerated, and intra-cochlear administration of SENS-501 was uneventful, and no serious adverse events or serious side effects have been reported. “The safety findings combined with the early efficacy signals observed so far in infants and toddlers support further clinical investigation of SENS-501,” said Nawal Ouzren, Chief Executive Officer of Sensorion. “Treating otoferlin-mediated congenital deafness before cochlear implantation and during heightened neural plasticity is essential to fully evaluate the potential of gene therapy as a monotherapy. We will continue to generate rigorous and comprehensive data to guide development decisions for this important patient population.” In children with age and baseline hearing characteristics comparable to those reported in recent publications, Sensorion has observed in the second cohort early directional improvements in two of the three treated patients by Month 3 on pure-tone audiometry. At Month 3, Patient 4 demonstrated a behavioural threshold of approximately 60 dB HL at the best-performing frequency, while Patient 5 demonstrated approximately 70 dB HL at the best-performing frequency. Follow-up is ongoing to assess the durability of these effects and the potential for further clinically meaningful functional gains. The Company will review the upcoming six-month efficacy data and will communicate during Q1 2026 once the dataset has reached sufficient maturity. About SENS-501 SENS-501 (OTOF-GT) is an innovative gene therapy program developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. This gene plays a key role in the transmission of auditory signals between the hair cells of the inner ear and the auditory nerve. When this gene is defective, affected individuals are born with severe to profound hearing loss. The aim of SENS-501 (OTOF-GT) is to restore hearing by introducing a functional copy of the OTOF gene directly into hair cells via viral vector technology (AAV). This therapy aims to restore the normal process of converting sound into electrical signals, enabling patients to regain their hearing ability. Currently in the clinical research phase, this gene therapy program represents significant hope for families affected by this rare form of genetic deafness. SENS-501 (OTOF-GT) embodies a commitment to scientific innovation in the field of hearing, with the potential to dramatically improve the quality of life of patients suffering from genetic deafness. This gene therapy for patients suffering from otoferlin deficiency has been developed in the framework of RHU AUDINNOVE, a consortium composed of Sensorion with the Necker Enfants Malades Hospital, the Institut Pasteur, and the Fondation pour l’Audition. The project is partially financed by the French National Research Agency, through the “investing for the future” program (ref: ANR-18-RHUS-0007). The OTOF gene targeted by the Audiogene trial was discovered in 1999 at the Institut Pasteur, by Prof. Christine Petit's team (Institut reConnect, Institut de l'Audition, Pasteur Institute), who also unraveled the pathophysiology of the corresponding deafness (DFNB9). About the Audiogene Trial Audiogene aims to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in infants and toddlers aged 6 to 31 months at the time of gene therapy treatment. By targeting the first years of life, when brain plasticity is optimal, the chances of these young children with pre-linguistic hearing loss acquiring normal speech and language are maximized. The study comprises two cohorts of two doses followed by an expansion cohort at the selected dose. While safety will be the primary endpoint of the first part of the dose escalation study, auditory brainstem response (ABR) will be the primary efficacy endpoint of the second part of the expansion. Audiogene will also evaluate the clinical safety, performance and ease-of-use of the delivery system developed by Sensorion. About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion’s portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion’s small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, has completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. www.sensorion.com Label: SENSORION ISIN: FR0012596468 Mnemonic: ALSEN Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its half-year 2025 results, provided a corporate update and announced the availability of the half-year report. “I’m really pleased with our progress in H1 2025, particularly, the rapid advancement of our SENS-501 gene therapy program,” commented Nawal Ouzren, Sensorion’s Chief Executive Officer. “The expedited enrollment pace in the Audiogene trial has enabled us to test two doses in less than a year in a strictly homogeneous population of infants and toddlers between the age of 6 months up to 31 months, naive of cochlear implants. As we eagerly await the Data Monitoring Committee’s recommendation and the analysis of data from Cohort 2 patients who received the higher dose, we continue to advance our development pipeline including gene therapy candidate SENS-601 (GJB2-GT) which is addressing multiple pathologies related to GJB2 mutations where preclinical activities are proceeding as planned towards a Clinical Trial Application in Q1 2026. In addition, we remain on track to report topline data results by year end 2025 from our Phase 2 clinical trial evaluating SENS-401, our small molecule program for Cisplatin-Induced Ototoxicity. This diversified approach across multiple modalities and indications positions us to capture significant value in the hearing loss market” Pipeline Highlights and Upcoming Milestones Gene Therapies for Hereditary Monogenic Hearing Loss In the first half of 2025, Sensorion progressed its portfolio of gene therapies developed in collaboration with the Institut Pasteur. It advanced its first gene therapy trial Audiogene which is evaluating SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, with the positive recommendation of the Data Monitoring Committee to escalate the dose into the second cohort. The Company also advanced its GJB2-GT program toward clinical development, with regulatory Clinical Trial Application (CTA) dossier currently being prepared for a submission expected in Q1 2026. SENS-501: Gene therapy program to restore hearing in OTOF patients SENS-501 has been developed as part of the Company’s collaboration focused on the genetics of hearing with the Institut Pasteur which was initiated in 2019 and extended for an additional 5-year period on January 5, 2024. It received Orphan Drug Designation from the European Commission in 2022 and was granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in 2022. SENS-501 is currently being investigated in a Phase 1/2 clinical trial, Audiogene, in Europe and Australia. Sensorion also received approval to initiate Audiogene in Germany. Audiogene aims to evaluate the safety, tolerability, and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in infants and toddlers aged 6 to 31 months at the time of gene therapy treatment. By targeting the first years of life, when the brain plasticity is optimal, the chances of these young children with pre-linguistic hearing loss of acquiring normal speech and language are maximized. The study comprises two cohorts and each are assessing different doses: 1.5E11 vg/vector/ear for the minimally effective dose in Cohort 1 and 4.5E11 vg/vector/ear for the second dose in Cohort 2, followed by an expansion cohort at the selected dose. Safety is the primary endpoint of the dose escalation study, and the efficacy endpoint of auditory brainstem response (ABR) is a secondary endpoint. As the trial progresses to the expansion cohort at the selected dose, the primary efficacy endpoint will be ABR. Audiogene also evaluates the clinical safety, performance and ease-of-use of the delivery system developed by Sensorion. On December 27, 2024, Sensorion completed the patient enrollment of the first cohort in the Audiogene trial, with all three patients aged 6 to 31 months and naive of cochlear implant having received an injection of SENS-501 gene therapy product in one ear. On February 21, 2025, Sensorion announced the positive recommendation from the Data Monitoring Committee (DMC) regarding the continuation of the study, following the review of the safety data of the first cohort. The Committee recommended that Audiogene proceed as planned with the assessment of the second dose, which is the escalation part of the trial. On July 1st, 2025, the Company announced positive preliminary data from the first cohort of the study, receiving the minimally effective dose of SENS-501 (1.5E11 vg/vector/ear). The Company reported a good safety profile of all five injected patients at that time (3 patients from Cohort 1 and 2 patients from Cohort 2). Sensorion also announced the preliminary positive response observed in Patient 3 (P3) at month 3 post injection, using standard hearing tests (Auditory Brainstem Response ABR, Pure Tone Audiometry PTA, and Patient (Parents) Reported Outcomes PROs). Three-month data from the Patient 3 include: Positive ABR responses at two frequencies, with the best frequency reaching 70 dB Improvement of hearing levels across two speech frequencies with best frequency reaching 90 dB level, per PTA Meaningful changes in responses to sounds and voices as reported by the parents with an IT-MAIS score increase of 16 points (145% relative improvement from baseline), and met expected auditory milestones based on an age-based parent questionnaire and according to the patient’s age (LittlEARS) On July 29, 2025, Sensorion announced the completion of patient enrollment of the second cohort in Audiogene, composed of three patients aged between 6 and 31 months who received a higher dose of SENS-501 (4.5E11 vg/vector/ear) in one ear. For all patients treated in the first and second cohorts, the surgical procedure was well tolerated: the intra-cochlear administration of the gene therapy product was uneventful. No serious adverse events and no serious side effects have been reported. Sensorion expects the Data Monitoring Committee by the end of the year 2025. OTOCONEX, the Company’s Natural History Study to document the natural course of disease progression in otoferlin deficiency patients and in children with hearing loss related to GJB2 mutations, continues to run across Europe and plays a key role in identifying eligible patients for Audiogene. GJB2-GT: Gene therapy program to restore hearing in GJB2 patients GJB2-GT is Sensorion's AAV-based gene therapy program initiated in 2021 and developed in collaboration with the Institut Pasteur to address three pathologies related to GJB2 mutations: pediatric congenital deafness, progressive forms of hearing loss in children, and early onset of presbycusis in adults. The Company advances its GJB2-GT program toward clinical development. The regulatory Clinical Trial Application (CTA) dossier is currently being prepared for a submission expected in Q1 2026. To support the CTA submission, Sensorion has started preliminary discussions with the American and European regulatory agencies in Q3 2025. SENS-401: Sensorion’s small molecule for the treatment and prevention of hearing loss SENS-401 (Arazasetron) is a small molecule that Sensorion is developing for three indications: (i) treatment of Sudden Sensorineural Hearing Loss SSNHL (Phase 2b completed), (ii) preservation of residual hearing following cochlear implantation, in partnership with Cochlear Limited (Phase 2a completed), and (iii) prevention of Cisplatin-Induced Ototoxicity (Phase 2a ongoing). SENS-401 is an orally available small molecule that aims at protecting and preserving inner ear tissue from damage, responsible for hearing impairment. It has been granted Orphan Drug Designation in Europe for the treatment of SSNHL, and in the U.S. for the prevention of Cisplatin-Induced Ototoxicity in pediatric population. SENS-401 to prevent Cisplatin-Induced Ototoxicity (CIO) The NOTOXIS Proof-of-Concept (POC) Phase 2a trial is a multicenter, randomized, controlled, open-label study designed to assess the efficacy of SENS-401 in preventing cisplatin-induced ototoxicity in adult patients with neoplastic disease, four weeks after completion of cisplatin-based chemotherapy. The trial assesses several endpoints, including the rate and severity of ototoxicity, changes in pure tone audiometry (PTA) (dB) throughout the study compared to before cisplatin treatment, and tolerability. Cisplatin and other platinum compounds are essential chemotherapeutic agents for many malignancies. Unfortunately, platinum-based therapies cause ototoxicity, or hearing loss, which is permanent, irreversible, and particularly harmful to 50-60% of adult patients and up to 90% of pediatric patients who survive cancer, representing a major unmet medical need for which there is no approved pharmaceutical treatment available. On September 20, 2024, Professor Yann Nguyen reported preliminary safety and efficacy data during the World Congress of Audiology. The preliminary data demonstrated that a cumulative dose of cisplatin is a key factor of ototoxicity severity. A good safety profile of SENS-401 was confirmed in the long term, with the drug being administered for the first time for an average duration of up to 23 weeks. The preliminary results suggest a trend toward an otoprotective effect of SENS-401 beyond a cisplatin dose of 300 mg/m2. Despite significantly higher exposure to cisplatin in the treatment group, most participants showed only mild ototoxicity. On March 7, 2025, Sensorion announced the completion of patient recruitment in NOTOXIS, and the trial is on track for Sensorion to report topline results by the end of H2 2025. Strengthening the Board of Directors On April 2, 2025, Sensorion announced the appointment of Amit Munshi as Chairman of the Board and Independent Director. Mr. Munshi brings to Sensorion approximately 35 years of experience in the healthcare industry with specific expertise in executive leadership having led multiple biotech companies to successful transformational growth milestones and exits. He was most recently the Chief Executive Officer of Orna Therapeutics, and previously ReNAgade Therapeutics which was acquired by Orna in May 2024. Mr. Munshi’s career includes serving as President and CEO of Arena Therapeutics (Nasdaq:ARNA) commencing in 2016, where he led the company’s transformation from a $300M market cap company into a late clinical stage organization, before its $6.7B acquisition by Pfizer (March 2022). Expected future milestones and estimated timelines: H2 2025 – SENS-501: Dose escalation Data Monitoring Committee H2 2025 – SENS-401 in Cisplatin-Induced Ototoxicity: Topline results Q1 2026 – GJB2-GT: Clinical Trial Application filing First-Half 2025 financial highlights Cash & Cash Equivalents, and short-term deposits, amounted to c. €57.1m as of June 30, 2025, compared to €77.0m as of December 31, 2024. R&D expenses increased by 2% from €14.7million in 2024 to €15.0 million in 2025. G&A expenses were €4.1 million for 2025, compared to €3.8 million for 2024. Net loss was -€16.0million for 2025, compared to -€13.9 million for 2024. Based on cash and cash equivalents and short-term deposit classified in other current assets of 57.1 million at 30 June 2025, the Company believes it has sufficient resources to finance its activities into the third quarter of 2026. Financial results The annual accounts as at June 30, 2025, were prepared according to IFRS standards and approved by the Board of Directors on September 16, 2025. The simplified income statement as of June 30, 2025, is as follows: In thousands of Euros – IFRS standards 30.06.2025 30.06.2024 Operating income 2,327 3,332 Research & Development expenses -15,001 -14,660 General & Administrative expenses -4,138 -3,791 Total operating expenses 19,139 18,451 Operating loss -16,812 -15,119 Financial result 804 1,323 Pre-tax current income -16,008 -13,796 Corporate Income Tax - -98 Net loss -16,008 -13,895 The simplified balance sheet as of June 30, 2025, is as follows: In thousands of Euros – IFRS standards 30.06.2025 31.12.2024 Non-current Assets 3,448 3,574 Other Current Assets 23,243 18,934 Of which short term deposit 10,417 10,214 Cash & cash equivalent 46,647 66,769 Total Assets 73,338 89,277 Equity 56,978 72,138 Non-current Liabilities 2,097 3,486 Current Liabilities 14 264 13,653 Total Liabilities 73 338 89,277 First-Half 2025 certified accounts On September 16, 2025, the Board of Directors approved the Company’s full year results as of June 30, 2025. The Half-Year Report can be found on Sensorion’s website (https://www.sensorion.com/en/home/) in the investor section under financial information. The half-year accounts of 2025 have been subject to a limited review by the Company’s statutory auditors, and an unqualified report has been issued on September 16, 2025. About SENS-501 SENS-501 (OTOF-GT) is an innovative gene therapy program developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. This gene plays a key role in the transmission of auditory signals between the hair cells of the inner ear and the auditory nerve. When this gene is defective, affected individuals are born with severe to profound hearing loss. The aim of SENS-501 (OTOF-GT) is to restore hearing by introducing a functional copy of the OTOF gene directly into hair cells via viral vector technology (AAV). This therapy aims to restore the normal process of converting sound into electrical signals, enabling patients to regain their hearing ability. Currently in the clinical research phase, this gene therapy program represents significant hope for families affected by this rare form of genetic deafness. SENS-501 (OTOF-GT) embodies a commitment to scientific innovation in the field of hearing, with the potential to dramatically improve the quality of life of patients suffering from genetic deafness. This gene therapy for patients suffering from otoferlin deficiency has been developed in the framework of RHU AUDINNOVE, a consortium composed of Sensorion with the Necker Enfants Malades Hospital, the Institut Pasteur, and the Fondation pour l’Audition. The project is partially financed by the French National Research Agency, through the “investing for the future” program (ref: ANR-18-RHUS-0007). The OTOF gene targeted by the Audiogene trial was discovered in 1999 at the Institut Pasteur, by Prof. Christine Petit's team (Institut reConnect, Institut de l'Audition, Pasteur Institute), who also unraveled the pathophysiology of the corresponding deafness (DFNB9). About the Audiogene trial Audiogene aims to evaluate the safety, tolerability, and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in infants and toddlers aged 6 to 31 months at the time of gene therapy treatment. By targeting the first years of life, when brain plasticity is optimal, the chances of these young children with pre-linguistic hearing loss acquiring normal speech and language are maximized. The study comprises two cohorts of two doses followed by an expansion cohort at the selected dose. While safety will be the primary endpoint of the first part of the dose escalation study, auditory brainstem response (ABR) will be the primary efficacy endpoint of the second part of the expansion. Audiogene will also evaluate the clinical safety, performance and ease-of-use of the delivery system developed by Sensorion. About SENS-401 SENS-401 (Arazasetron), Sensorion’s clinical stage lead drug candidate, is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment. Sensorion developed SENS-401 in three Phase 2 clinical trials: (i) for the prevention of Cisplatin-Induced Ototoxicity, (ii) to prevent residual hearing loss in patients scheduled for cochlear implantation, and (iii) to treat sudden sensorineural hearing loss. The last two studies are completed. SENS-401 has been granted Orphan Drug Designation by the EMA in Europe for the treatment of sudden sensorineural hearing loss, and by the FDA in the U.S. for the prevention of platinum-induced ototoxicity in pediatric population. About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion’s portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion’s small molecule progressed in three Phase 2 proof of concept clinical study: firstly, in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing, for which the recruitment is completed, and the follow-up is ongoing. Secondly, with partner Cochlear Limited, a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation, completed in 2024. Thirdly, a Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in 2022. www.sensorion.com Label: SENSORION ISIN: FR0012596468 Mnemonic: ALSEN Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2023 full year report published on March 14, 2024, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.